FDA approves rituximab + hyaluronidase human for FL, DLBCL, and CLLJune 22, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersFollicular Lymphoma
Bendamustine plus rituximab may have edge for treating indolent NHL, MCLJune 22, 2017Lymphoma & Plasma Cell Disorders
Lenalidomide-rituximab induces high CR rate in untreated follicular lymphomaJune 21, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
GALEN safe and effective in relapsed and refractory follicular lymphomaJune 20, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Len plus anti-CD19 Mab MOR208 active against advanced DLBCLJune 20, 2017Lymphoma & Plasma Cell Disorders
Novel CAR T cells drive high objective response rate in multiple myelomaJune 12, 2017Lymphoma & Plasma Cell Disorders
Smoldering myeloma progressed more rapidly in patients with elevated BMIsMay 19, 2017Lymphoma & Plasma Cell Disorders
Myeloma patients who get solid tumor cancers do as well as other cancer patientsMay 19, 2017Lymphoma & Plasma Cell Disorders
Lenalidomide maintenance boosted depth of response in myeloma patientsMay 19, 2017Lymphoma & Plasma Cell Disorders
Subcutaneous rituximab safe, effective for follicular lymphomaMay 9, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Early-stage HL patients fare well 10 years after lower-intensity regimensMay 5, 2017Lymphoma & Plasma Cell Disorders
